VXRT Vaxart

Vaxart to Provide 2021 Business Outlook on Tuesday, March 2, 2021

Vaxart to Provide 2021 Business Outlook on Tuesday, March 2, 2021

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will host a conference call and provide a business update at 4:30 PM ET on Tuesday, March 2, 2021.

Conference Call Dial-In & Webcast Information:
Date: Tuesday, March 2, 2021
Time:4:30 PM Eastern Time
Domestic:877-407-0784
International:201-689-8560
Conference ID:13716984
Webcast:
  

About Vaxart

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart has believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contacts
 
Brant Biehn

Vaxart, Inc.

650 550 3500

Joyce Allaire

LifeSci Advisors, LLC

617 435 6602





EN
24/02/2021

Underlying

VXRTVaxart

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vaxart

 PRESS RELEASE
Free
VXRT VAXART

Vaxart Announces Trading on OTCQX Best Market

Vaxart Announces Trading on OTCQX Best Market SOUTH SAN FRANCISCO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced its common stock has been approved to trade on the OTCQX® Best Market. The Company’s shares will commence trading at the open of the market on July 8, 2025, under its existing ticker symbol “VXRT.” Shareholders will not need to take any action. The OTCQX Market, being the highe...

July 8, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Preliminary results from the Annual Meeting indicate that two proposals were approved and two proposals were rejected by Vaxart stockholders. Stockholders voted in favor of...

June 13, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Ge...

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology - Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies (141% and 94%, respectively) compared with first-generation constructs, supporting potential for improved protection against infection - - Vaccine candidates were safe and well-tolerated across all dose groups with no vaccine-related serious adverse events reported - - Conference call...

June 11, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Top...

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time t...

June 10, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Announces Adjournment of Annual Meeting of Stockholders

Vaxart Announces Adjournment of Annual Meeting of Stockholders Meeting adjourned to June 13, 2025 at 8:30 a.m. Pacific Time Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on June 12, 2025 Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”) announced today that its 2025 annual meeting of stockholders (the “Annual Meeting”) has been adjourned to Friday, June 13, 2025...

June 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch